Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy

Authors:

Abstract
To evaluate the efficacy of adjunctive aripiprazole in patients with minimal response to prior antidepressant therapy (ADT). Pooled data from three randomized, double-blind, placebo-controlled studies assessing the efficacy of adjunctive aripiprazole to ADT in patients with major depressive disorder who had a minimal response [<25% reduction on the Montgomery-Asberg Depression Rating Scale (MADRS)] to an 8-week prospective ADT. During the 6-week, double-blind adjunctive phase, response was defined as at least 50% reduction in the MADRS score and remission as at least 50% reduction in MADRS score and a MADRS score <= 10. Rates were examined using analysis of covariance and Cochran-Mantel-Haenszel tests. Kaplan-Meier curves were used to calculate time to response and remission. Of 1038 patients, 72% (n=746) exhibited a minimal response to ADT (ADT minimal responder). Time to response and remission were significantly shorter for ADT minimal responders receiving aripiprazole + ADT versus adjunctive placebo + ADT. ADT minimal responders on aripiprazole + ADT showed significantly greater improvements in MADRS score at endpoint compared with minimal responders on placebo + ADT (-10.3 vs. -6.5, P < 0.0001). In addition, ADT minimal responders exhibited significantly higher response rates with aripiprazole + ADT than placebo + ADT (36 vs. 19%, respectively, P < 0.0001) and higher remission rates (24 vs. 12%, respectively, P < 0.0001). The numbers needed to treat with aripiprazole + ADT were six for response and eight for remission. Aripiprazole augmentation had a rapid and clinically meaningful effect in ADT minimal responders. Int Clin Psychopharmacol 27: 125-133 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.